Mostrando 2 resultados de: 2
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
ArticleAbstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injectiPalabras claves:B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptakeAutores:Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.Fuentes:scopusPhase i/ii clinical trial of the humanized anti-egf-r monoclonal antibody h-r3 labelled with <sup>99m</sup>tc in patients with tumour of epithelial origin
ArticleAbstract: To evaluate the biodistribution, internal radiation dosimetry and toxicity of the humanized MAb h-R3Palabras claves:biodistribution, Dosimetry, Humanized MAb, RadioimmunodiagnosisAutores:Aguilar V., Batista J.F., Coca M.A., Hernández A., Iznaga-Escobar N., Neninger Vinageras E., Perera A., Pérez M., Ramos M., Romero S., Sánchez E., Tania Crombet, Torres L.Fuentes:scopus